These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2713865)

  • 1. Piribedil therapy in Parkinson's disease. Use of the drug in the retard form.
    Mentenopoulos G; Katsarou Z; Bostantjopoulou S; Logothetis J
    Clin Neuropharmacol; 1989 Feb; 12(1):23-8. PubMed ID: 2713865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Piribedil in the treatment of Parkinson disease (author's transl)].
    Nardini M; Sciannandrone R; Fieschi C; De Simone G
    Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
    Truelle JL; Chanelet J; Bastard J; Six P; Emile J
    Nouv Presse Med; 1977 Oct; 6(33):2987-90. PubMed ID: 22844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piribedil--an oral dopamine agonist for treatment of Parkinson's disease.
    Sweet RD; Wasterlain C; McDowell FH
    Trans Am Neurol Assoc; 1974; 99():258-60. PubMed ID: 4463553
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
    Emile J; Chanelet J; Truelle JL; Bastard J
    Adv Neurol; 1975; 9():409-13. PubMed ID: 1096577
    [No Abstract]   [Full Text] [Related]  

  • 11. Studies on piribedil in Parkinsonism.
    Lieberman AN; Shopsin B; Brun YL; Boal D; Zolfaghari M
    Adv Neurol; 1975; 9():399-407. PubMed ID: 125032
    [No Abstract]   [Full Text] [Related]  

  • 12. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
    Rondot P; Bathien N; Dumas JL
    Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574
    [No Abstract]   [Full Text] [Related]  

  • 13. Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
    Feigenson JS; Sweet RD; McDowell FH
    Neurology; 1976 May; 26(5):430-3. PubMed ID: 944394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actions of dopaminergic agonists in parkinsonism.
    McDowell FH; Sweet R
    Adv Neurol; 1975; 9():367-71. PubMed ID: 1096573
    [No Abstract]   [Full Text] [Related]  

  • 16. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
    Simon N; Micallef J; Reynier JC; Lesourd M; Witjas T; Alicherif A; Azulay JP; Blin O
    Mov Disord; 2005 Jul; 20(7):803-9. PubMed ID: 15726579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piribedil in Parkinson's syndrome: a clinical study.
    Engel J; Granerus AK; Svanborg A
    Eur J Clin Pharmacol; 1975 Apr; 8(3-4):223-6. PubMed ID: 183960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
    Callaghan N; Fitzpatrick E; O'Mahony JB
    Acta Neurol Scand; 1975 Sep; 52(3):179-86. PubMed ID: 1098359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
    Turle-Lorenzo N; Maurin B; Puma C; Chezaubernard C; Morain P; Baunez C; Nieoullon A; Amalric M
    J Pharmacol Exp Ther; 2006 Nov; 319(2):914-23. PubMed ID: 16920993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.